ING Groep NV Lowers Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

ING Groep NV cut its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 42.9% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 72,248 shares of the medical equipment provider’s stock after selling 54,248 shares during the period. ING Groep NV’s holdings in Intuitive Surgical were worth $35,493,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ISRG. Hazlett Burt & Watson Inc. lifted its position in Intuitive Surgical by 5.8% during the third quarter. Hazlett Burt & Watson Inc. now owns 362 shares of the medical equipment provider’s stock worth $177,000 after buying an additional 20 shares during the period. Mitchell Mcleod Pugh & Williams Inc. lifted its holdings in shares of Intuitive Surgical by 4.1% during the 3rd quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 503 shares of the medical equipment provider’s stock worth $247,000 after acquiring an additional 20 shares during the period. Ullmann Wealth Partners Group LLC boosted its position in shares of Intuitive Surgical by 1.6% in the third quarter. Ullmann Wealth Partners Group LLC now owns 1,329 shares of the medical equipment provider’s stock worth $653,000 after acquiring an additional 21 shares during the last quarter. One Wealth Management Investment & Advisory Services LLC grew its holdings in Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after purchasing an additional 23 shares during the period. Finally, Falcon Wealth Planning raised its stake in Intuitive Surgical by 0.4% during the third quarter. Falcon Wealth Planning now owns 5,693 shares of the medical equipment provider’s stock worth $2,797,000 after purchasing an additional 23 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG traded up $6.84 during midday trading on Thursday, reaching $543.53. 397,463 shares of the company’s stock were exchanged, compared to its average volume of 1,454,509. Intuitive Surgical, Inc. has a 52-week low of $291.39 and a 52-week high of $544.38. The business’s fifty day moving average price is $496.95 and its two-hundred day moving average price is $455.65. The stock has a market capitalization of $193.59 billion, a PE ratio of 86.28, a price-to-earnings-growth ratio of 5.28 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The company had revenue of $2.04 billion for the quarter, compared to the consensus estimate of $2.01 billion. Analysts predict that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the transaction, the director now directly owns 821 shares of the company’s stock, valued at $402,519.88. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 396 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $486.88, for a total transaction of $192,804.48. Following the completion of the sale, the executive vice president now owns 5,506 shares in the company, valued at $2,680,761.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the transaction, the director now owns 821 shares in the company, valued at approximately $402,519.88. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 91,178 shares of company stock worth $45,897,071. Insiders own 0.90% of the company’s stock.

Analysts Set New Price Targets

ISRG has been the subject of several research reports. The Goldman Sachs Group set a $604.00 price objective on shares of Intuitive Surgical in a research note on Friday, October 18th. Mizuho boosted their price target on Intuitive Surgical from $440.00 to $500.00 in a research report on Thursday, October 17th. Barclays raised their price objective on Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a report on Thursday, July 18th. BTIG Research set a $535.00 target price on Intuitive Surgical in a report on Friday, October 18th. Finally, Raymond James raised their price target on shares of Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a report on Monday, October 14th. One analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $513.74.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.